Life Science

Formulation: 3% BSA in PBS plus 0.02% Azide

An irreversible, noncompetitive inhibitor of PARP1 that disrupts binding between PARP1 and DNA by interacting with the DNA binding domain produces rapid apoptosis in the various cancer cell (IC50s = 40-128 &muM).

An irreversible, noncompetitive inhibitor of PARP1 that disrupts binding between PARP1 and DNA by interacting with the DNA binding domain produces rapid apoptosis in the various cancer cell (IC50s = 40-128 &muM).

An irreversible, noncompetitive inhibitor of PARP1 that disrupts binding between PARP1 and DNA by interacting with the DNA binding domain produces rapid apoptosis in the various cancer cell (IC50s = 40-128 &muM).

A popular non-cleavable, membrane-impermeable, water-soluble DSS analog Category: Amine-reactive Reactive Groups: sulfo-NHS-ester Reactive Toward: amino grops Water Soluble: Yes Membrane Permeable: No Cleavability: Non-cleavable MW: 572.43

A popular non-cleavable, membrane-impermeable, water-soluble DSS analog Category: Amine-reactive Reactive Groups: sulfo-NHS-ester Reactive Toward: amino grops Water Soluble: Yes Membrane Permeable: No Cleavability: Non-cleavable MW: 572.43

A low affinity calcium indicator (Kd = 7-26 &microM) with long excitation wavelengths (400/485 nm) that is suitable for detecting elevated calcium levels associated with activation of smooth muscle, neurons, and intracellular calcium stores.

A cell-permeant low affinity calcium indicator (Kd = ~7 uM) that exhibits a shift in excitation maximum from about 480 nm to 400 nm upon binding calcium, enabling ratiometric calcium measurements.

AVL-292 is a Bruton’s tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).

AVL-292 is a Bruton’s tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).

AVL-292 is a Bruton’s tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).

A cell-permeable, cyclic nucleotide derivative that mimics the action of endogenous cAMP and is a phosphodiesterase inhibitor.